The GENEROUS Model: What it Means for Life Science Companies, States and Patients 

With the Centers for Medicare & Medicaid Services’ (CMS) announcement of the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, life science companies, states and other stakeholders are seeking to understand how the Most Favored Nation (MFN) pricing model may impact them and Medicaid patients seeking access to drugs.

To help answer these and any other questions, join Manatt Health for a deep dive conversation during which we will cover:  

• An overview of the GENEROUS Model and participation requirements
• MFN pricing metrics and how they compare to those previously used by CMS
• What the application entails
• Opportunities and risks of applying and participating for both pharmaceutical manufacturers and state Medicaid programs
• Outstanding questions on the model’s design

Panelists:

• , Partner, Manatt Health
• , Partner, Manatt Health
• , Manager, Manatt Health

Date and Time:

Tuesday, December 9
1:00 – 2:00 p.m. ET
10:00 – 11:00 a.m. PT